Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031928 · ClinicalTrials.gov registry record · Phase 1
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 3,000
- Enrollment target
- 9
- Study locations
NCT00031928 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 3,000 participants, above the 117-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (2464% higher). The trial reports 9 study locations across 8 states.
The verdict
NCT00031928, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3,000 participants
- Enrollment target
- 9
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to determine the effectiveness of mafosfamide in treating patients who have progressive or refractory meningeal tumors.
Conditions Studied
Interventions
- DRUG mafosfamide
Study Locations (9)
Texas
- Texas Children's Cancer Center - Houston
- University of Texas - MD Anderson Cancer Center - Houston
California
- Children's Hospital Los Angeles - Los Angeles
District of Columbia
- Children's National Medical Center - Washington D.C.
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
Minnesota
- Mayo Clinic Cancer Center - Rochester
Vermont
- Neurological Research Center, Inc. - Bennington
Washington
- Children's Hospital and Regional Medical Center - Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031928
The ClinicalTrials.gov registry entry for NCT00031928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 117-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (2464% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which mafosfamide is the first listed.
NCT00031928 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00031928 about?
NCT00031928 is a clinical study titled "Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to determine the effectiveness of mafosfamide in treating patients who have progressive or refractory meningeal tumors.
What is the current status of trial NCT00031928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3,000 participants. The study started on 2002-01.
What conditions does trial NCT00031928 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00031928?
The interventions under investigation include: mafosfamide (DRUG).
Who is sponsoring clinical trial NCT00031928?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031928 being conducted?
This trial has 9 study locations across California, District of Columbia, Maryland, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.